Epšteino–Bar virusas (Lithuanian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Epšteino–Bar virusas" in Lithuanian language version.

refsWebsite

Global rank Lithuanian rank

29nih.gov

4^th place

12^th place

19doi.org

2^nd place

10^th place

6semanticscholar.org

11^th place

926^th place

4web.archive.org

1^st place

3cdc.gov

218^th place

292^nd place

2harvard.edu

18^th place

42^nd place

1vlk.lt

low place

1,233^rd place

1lrv.lt

low place

49^th place

1archive.org

6^th place

14^th place

1cancerresearchuk.org

8,489^th place

low place

1bbc.co.uk

8^th place

21^st place

archive.org

Gandhi MK, Tellam JT, Khanna R (2004). „Epstein-Barr virus-associated Hodgkin's lymphoma“. British Journal of Haematology. 125 (3): 267–281. doi:10.1111/j.1365-2141.2004.04902.x. PMID 15086409. S2CID 2355660.

bbc.co.uk

McGrath P (2014-04-06). „Cancer virus discovery helped by delayed flight“. Health. BBC News. Suarchyvuota iš originalo 2015-10-08. Nuoroda tikrinta 2015-11-04.

cancerresearchuk.org

„Developing a vaccine for the Epstein–Barr virus could prevent up to 200,000 cancers globally say experts“. Cancer Research UK. 2014-03-24. Suarchyvuota iš originalo 2017-03-19.

cdc.gov

„About 90% of adults have antibodies that show that they have a current or past EBV infection“. National Center for Infectious Diseases. US Centers for Disease Control. 2020-09-28. Suarchyvuota iš originalo 2016-08-08.
„Epstein–Barr virus and infectious Mononucleosis“. U.S. Centers for Disease Control and Prevention (CDC). Suarchyvuotas originalas 2012-04-20. Nuoroda tikrinta 2011-12-29.
„Epstein-Barr Virus and Infectious Mononucleosis – Laboratory Testing“. U.S. Centers for Disease Control and Prevention (CDC). Nuoroda tikrinta 2024-03-22.

doi.org

Zanella M, Cordey S, Kaiser L (2020). „Beyond cytomegalovirus and Epstein-Barr virus: A feview of viruses composing the blood virome of solid organ transplant and hematopoietic stem cell transplant recipients“. Clinical Microbiology Reviews. 33 (4): e00027-20. doi:10.1128/CMR.00027-20. PMC 7462738. PMID 32847820.
Zhong L, Krummenacher C, Zhang W, Hong J, Feng Q, Chen Y, Zhao Q, Zeng MS, Zeng YX, Xu M, Zhang X (2022). „Urgency and necessity of Epstein-Barr virus prophylactic vaccines“. NPJ Vaccines. 7 (1): 159. doi:10.1038/s41541-022-00587-6. PMID 36494369.
Dunmire SK, Verghese PS, Balfour HH (2018). „Primary Epstein-Barr virus infection“. J Clin Virol. 102: 84–92. doi:10.1016/j.jcv.2018.03.001. PMID 29525635.
Amon W, Farrell PJ (2004). „Reactivation of Epstein-Barr virus from latency“. Reviews in Medical Virology. 15 (3): 149–156. doi:10.1002/rmv.456. PMID 15546128. S2CID 19433994.
Straus SE, Cohen JI, Tosato G, Meier J (1993). „NIH conference. Epstein-Barr virus infections: Biology, pathogenesis, and management“. Annals of Internal Medicine. 118 (1): 45–58. doi:10.7326/0003-4819-118-1-199301010-00009. PMID 8380053. S2CID 53090545.
Proal AD, VanElzakker MB (2021-06-23). „Long COVID or post-acute sequelae of COVID-19 (PASC): An overview of biological factors that may contribute to persistent symptoms“. Frontiers in Microbiology. 12: 698169. doi:10.3389/fmicb.2021.698169. PMC 8260991. PMID 34248921.
Pannone G, Zamparese R, Pace M, Pedicillo MC, Cagiano S, Somma P, et al. (2014). „The role of EBV in the pathogenesis of Burkitt's Lymphoma: an Italian hospital based survey“. Infectious Agents and Cancer. 9 (1): 34. doi:10.1186/1750-9378-9-34. PMC 4216353. PMID 25364378.
Bereikienė S, Rascon J (2017). „Hemofagocitinė limfohistiocitozė: literatūros apžvalga“. Acta Med Litu. 24 (1): 51–66. doi:10.6001/actamedica.v24i1.3463. PMC 5467963. PMID 28630593.
Gandhi MK, Tellam JT, Khanna R (2004). „Epstein-Barr virus-associated Hodgkin's lymphoma“. British Journal of Haematology. 125 (3): 267–281. doi:10.1111/j.1365-2141.2004.04902.x. PMID 15086409. S2CID 2355660.
Maeda E, Akahane M, Kiryu S, Kato N, Yoshikawa T, Hayashi N, et al. (2009). „Spectrum of Epstein-Barr virus-related diseases: A pictorial review“. Japanese Journal of Radiology. 27 (1): 4–19. doi:10.1007/s11604-008-0291-2. PMID 19373526. S2CID 6970917.
Toussirot E, Roudier J (2008). „Epstein-Barr virus in autoimmune diseases“. Best Practice & Research: Clinical Rheumatology. 22 (5): 883–896. doi:10.1016/j.berh.2008.09.007. PMID 19028369.
Dreyfus DH (2011). „Autoimmune disease: A role for new anti-viral therapies?“. Autoimmunity Reviews. 11 (2): 88–97. doi:10.1016/j.autrev.2011.08.005. PMID 21871974.
Pender MP (2012). „CD8+ T cell deficiency, Epstein-Barr virus infection, vitamin D deficiency, and steps to autoimmunity: A unifying hypothesis“. Autoimmune Diseases. 2012: 189096. doi:10.1155/2012/189096. PMC 3270541. PMID 22312480.
Khan G, Fitzmaurice C, Naghavi M, Ahmed LA (2020). „Global and regional incidence, mortality and disability-adjusted life-years for Epstein-Barr virus-attributable malignancies, 1990–2017“. BMJ Open. 10 (8): e037505. doi:10.1136/bmjopen-2020-037505. PMC 7462312. PMID 32868361.
Kimura H, Cohen JI (2017). „Chronic Active Epstein-Barr Virus Disease“. Front Immunol. 8: 1867. doi:10.3389/fimmu.2017.01867. PMC 5770746. PMID 29375552.{{cite journal}}: CS1 priežiūra: unflagged free DOI (link)
Robinson WH, Steinman L (2022). „Epstein-Barr virus and multiple sclerosis“. Science (anglų). 375 (6578): 264–265. Bibcode:2022Sci...375..264R. doi:10.1126/science.abm7930. PMID 35025606. S2CID 245978874.
Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, et al. (2022). „Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis“. Science. American Association for the Advancement of Science (AAAS). 375 (6578): 296–301. Bibcode:2022Sci...375..296B. doi:10.1126/science.abj8222. PMID 35025605. S2CID 245983763.
Cohen JI (2020). „Herpesvirus latency“. J Clin Invest. 130 (7): 3361–3369. doi:10.1172/JCI136225. PMC 7324166. PMID 32364538.
Epstein MA, Achong BG, Barr YM (1964). „Virus Particles in Cultured Lymphoblasts from Burkitt's Lymphoma“. Lancet. 1 (7335): 702–703. doi:10.1016/s0140-6736(64)91524-7. PMID 14107961.

harvard.edu

ui.adsabs.harvard.edu

Robinson WH, Steinman L (2022). „Epstein-Barr virus and multiple sclerosis“. Science (anglų). 375 (6578): 264–265. Bibcode:2022Sci...375..264R. doi:10.1126/science.abm7930. PMID 35025606. S2CID 245978874.
Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, et al. (2022). „Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis“. Science. American Association for the Advancement of Science (AAAS). 375 (6578): 296–301. Bibcode:2022Sci...375..296B. doi:10.1126/science.abj8222. PMID 35025605. S2CID 245983763.

lrv.lt

nvsc.lrv.lt

„Infekcinė mononukleozė“. Nacionalinis visuomenės sveikatos centras prie Sveikatos apsaugos ministerijos. 2023-11-20. Nuoroda tikrinta 2023-11-20.

nih.gov

pubmed.ncbi.nlm.nih.gov

Zanella M, Cordey S, Kaiser L (2020). „Beyond cytomegalovirus and Epstein-Barr virus: A feview of viruses composing the blood virome of solid organ transplant and hematopoietic stem cell transplant recipients“. Clinical Microbiology Reviews. 33 (4): e00027-20. doi:10.1128/CMR.00027-20. PMC 7462738. PMID 32847820.
Zhong L, Krummenacher C, Zhang W, Hong J, Feng Q, Chen Y, Zhao Q, Zeng MS, Zeng YX, Xu M, Zhang X (2022). „Urgency and necessity of Epstein-Barr virus prophylactic vaccines“. NPJ Vaccines. 7 (1): 159. doi:10.1038/s41541-022-00587-6. PMID 36494369.
Dunmire SK, Verghese PS, Balfour HH (2018). „Primary Epstein-Barr virus infection“. J Clin Virol. 102: 84–92. doi:10.1016/j.jcv.2018.03.001. PMID 29525635.
Amon W, Farrell PJ (2004). „Reactivation of Epstein-Barr virus from latency“. Reviews in Medical Virology. 15 (3): 149–156. doi:10.1002/rmv.456. PMID 15546128. S2CID 19433994.
Straus SE, Cohen JI, Tosato G, Meier J (1993). „NIH conference. Epstein-Barr virus infections: Biology, pathogenesis, and management“. Annals of Internal Medicine. 118 (1): 45–58. doi:10.7326/0003-4819-118-1-199301010-00009. PMID 8380053. S2CID 53090545.
Schooley RT (1988). „Chronic fatigue syndrome: A manifestation of Epstein-Barr virus infection?“. Current Clinical Topics in Infectious Diseases. 9: 126–146. PMID 2855828.
Proal AD, VanElzakker MB (2021-06-23). „Long COVID or post-acute sequelae of COVID-19 (PASC): An overview of biological factors that may contribute to persistent symptoms“. Frontiers in Microbiology. 12: 698169. doi:10.3389/fmicb.2021.698169. PMC 8260991. PMID 34248921.
Pannone G, Zamparese R, Pace M, Pedicillo MC, Cagiano S, Somma P, et al. (2014). „The role of EBV in the pathogenesis of Burkitt's Lymphoma: an Italian hospital based survey“. Infectious Agents and Cancer. 9 (1): 34. doi:10.1186/1750-9378-9-34. PMC 4216353. PMID 25364378.
Bereikienė S, Rascon J (2017). „Hemofagocitinė limfohistiocitozė: literatūros apžvalga“. Acta Med Litu. 24 (1): 51–66. doi:10.6001/actamedica.v24i1.3463. PMC 5467963. PMID 28630593.
Gandhi MK, Tellam JT, Khanna R (2004). „Epstein-Barr virus-associated Hodgkin's lymphoma“. British Journal of Haematology. 125 (3): 267–281. doi:10.1111/j.1365-2141.2004.04902.x. PMID 15086409. S2CID 2355660.
Maeda E, Akahane M, Kiryu S, Kato N, Yoshikawa T, Hayashi N, et al. (2009). „Spectrum of Epstein-Barr virus-related diseases: A pictorial review“. Japanese Journal of Radiology. 27 (1): 4–19. doi:10.1007/s11604-008-0291-2. PMID 19373526. S2CID 6970917.
Toussirot E, Roudier J (2008). „Epstein-Barr virus in autoimmune diseases“. Best Practice & Research: Clinical Rheumatology. 22 (5): 883–896. doi:10.1016/j.berh.2008.09.007. PMID 19028369.
Dreyfus DH (2011). „Autoimmune disease: A role for new anti-viral therapies?“. Autoimmunity Reviews. 11 (2): 88–97. doi:10.1016/j.autrev.2011.08.005. PMID 21871974.
Pender MP (2012). „CD8+ T cell deficiency, Epstein-Barr virus infection, vitamin D deficiency, and steps to autoimmunity: A unifying hypothesis“. Autoimmune Diseases. 2012: 189096. doi:10.1155/2012/189096. PMC 3270541. PMID 22312480.
Khan G, Fitzmaurice C, Naghavi M, Ahmed LA (2020). „Global and regional incidence, mortality and disability-adjusted life-years for Epstein-Barr virus-attributable malignancies, 1990–2017“. BMJ Open. 10 (8): e037505. doi:10.1136/bmjopen-2020-037505. PMC 7462312. PMID 32868361.
Kimura H, Cohen JI (2017). „Chronic Active Epstein-Barr Virus Disease“. Front Immunol. 8: 1867. doi:10.3389/fimmu.2017.01867. PMC 5770746. PMID 29375552.{{cite journal}}: CS1 priežiūra: unflagged free DOI (link)
Robinson WH, Steinman L (2022). „Epstein-Barr virus and multiple sclerosis“. Science (anglų). 375 (6578): 264–265. Bibcode:2022Sci...375..264R. doi:10.1126/science.abm7930. PMID 35025606. S2CID 245978874.
Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, et al. (2022). „Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis“. Science. American Association for the Advancement of Science (AAAS). 375 (6578): 296–301. Bibcode:2022Sci...375..296B. doi:10.1126/science.abj8222. PMID 35025605. S2CID 245983763.
Cohen JI (2020). „Herpesvirus latency“. J Clin Invest. 130 (7): 3361–3369. doi:10.1172/JCI136225. PMC 7324166. PMID 32364538.
Epstein MA, Achong BG, Barr YM (1964). „Virus Particles in Cultured Lymphoblasts from Burkitt's Lymphoma“. Lancet. 1 (7335): 702–703. doi:10.1016/s0140-6736(64)91524-7. PMID 14107961.

ncbi.nlm.nih.gov

Zanella M, Cordey S, Kaiser L (2020). „Beyond cytomegalovirus and Epstein-Barr virus: A feview of viruses composing the blood virome of solid organ transplant and hematopoietic stem cell transplant recipients“. Clinical Microbiology Reviews. 33 (4): e00027-20. doi:10.1128/CMR.00027-20. PMC 7462738. PMID 32847820.
Zhong L, Krummenacher C, Zhang W, Hong J, Feng Q, Chen Y, Zhao Q, Zeng MS, Zeng YX, Xu M, Zhang X (2022). „Urgency and necessity of Epstein-Barr virus prophylactic vaccines“. NPJ Vaccines. 7 (1): 159. doi:10.1038/s41541-022-00587-6. PMID 36494369.
Proal AD, VanElzakker MB (2021-06-23). „Long COVID or post-acute sequelae of COVID-19 (PASC): An overview of biological factors that may contribute to persistent symptoms“. Frontiers in Microbiology. 12: 698169. doi:10.3389/fmicb.2021.698169. PMC 8260991. PMID 34248921.
Pannone G, Zamparese R, Pace M, Pedicillo MC, Cagiano S, Somma P, et al. (2014). „The role of EBV in the pathogenesis of Burkitt's Lymphoma: an Italian hospital based survey“. Infectious Agents and Cancer. 9 (1): 34. doi:10.1186/1750-9378-9-34. PMC 4216353. PMID 25364378.
Bereikienė S, Rascon J (2017). „Hemofagocitinė limfohistiocitozė: literatūros apžvalga“. Acta Med Litu. 24 (1): 51–66. doi:10.6001/actamedica.v24i1.3463. PMC 5467963. PMID 28630593.
Pender MP (2012). „CD8+ T cell deficiency, Epstein-Barr virus infection, vitamin D deficiency, and steps to autoimmunity: A unifying hypothesis“. Autoimmune Diseases. 2012: 189096. doi:10.1155/2012/189096. PMC 3270541. PMID 22312480.
Khan G, Fitzmaurice C, Naghavi M, Ahmed LA (2020). „Global and regional incidence, mortality and disability-adjusted life-years for Epstein-Barr virus-attributable malignancies, 1990–2017“. BMJ Open. 10 (8): e037505. doi:10.1136/bmjopen-2020-037505. PMC 7462312. PMID 32868361.
Kimura H, Cohen JI (2017). „Chronic Active Epstein-Barr Virus Disease“. Front Immunol. 8: 1867. doi:10.3389/fimmu.2017.01867. PMC 5770746. PMID 29375552.{{cite journal}}: CS1 priežiūra: unflagged free DOI (link)
Cohen JI (2020). „Herpesvirus latency“. J Clin Invest. 130 (7): 3361–3369. doi:10.1172/JCI136225. PMC 7324166. PMID 32364538.

semanticscholar.org

api.semanticscholar.org

Amon W, Farrell PJ (2004). „Reactivation of Epstein-Barr virus from latency“. Reviews in Medical Virology. 15 (3): 149–156. doi:10.1002/rmv.456. PMID 15546128. S2CID 19433994.
Straus SE, Cohen JI, Tosato G, Meier J (1993). „NIH conference. Epstein-Barr virus infections: Biology, pathogenesis, and management“. Annals of Internal Medicine. 118 (1): 45–58. doi:10.7326/0003-4819-118-1-199301010-00009. PMID 8380053. S2CID 53090545.
Gandhi MK, Tellam JT, Khanna R (2004). „Epstein-Barr virus-associated Hodgkin's lymphoma“. British Journal of Haematology. 125 (3): 267–281. doi:10.1111/j.1365-2141.2004.04902.x. PMID 15086409. S2CID 2355660.
Maeda E, Akahane M, Kiryu S, Kato N, Yoshikawa T, Hayashi N, et al. (2009). „Spectrum of Epstein-Barr virus-related diseases: A pictorial review“. Japanese Journal of Radiology. 27 (1): 4–19. doi:10.1007/s11604-008-0291-2. PMID 19373526. S2CID 6970917.
Robinson WH, Steinman L (2022). „Epstein-Barr virus and multiple sclerosis“. Science (anglų). 375 (6578): 264–265. Bibcode:2022Sci...375..264R. doi:10.1126/science.abm7930. PMID 35025606. S2CID 245978874.
Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, et al. (2022). „Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis“. Science. American Association for the Advancement of Science (AAAS). 375 (6578): 296–301. Bibcode:2022Sci...375..296B. doi:10.1126/science.abj8222. PMID 35025605. S2CID 245983763.

vlk.lt

ebook.vlk.lt

„KRAUJO IR KRAUJODAROS ORGANŲ LIGOS BEI TAM TIKRI SUTRIKIMAI, SUSIJĘ SU IMUNINIAIS MECHANIZMAIS (D50-D89): D82 Imunodeficitas kartu su kitais pagrindiniais sutrikimais]“. TLK-10-AM / ACHI / ACS elektroninis vadovas. Nuoroda tikrinta 2024-03-22.

web.archive.org

„About 90% of adults have antibodies that show that they have a current or past EBV infection“. National Center for Infectious Diseases. US Centers for Disease Control. 2020-09-28. Suarchyvuota iš originalo 2016-08-08.
„Epstein–Barr virus and infectious Mononucleosis“. U.S. Centers for Disease Control and Prevention (CDC). Suarchyvuotas originalas 2012-04-20. Nuoroda tikrinta 2011-12-29.
„Developing a vaccine for the Epstein–Barr virus could prevent up to 200,000 cancers globally say experts“. Cancer Research UK. 2014-03-24. Suarchyvuota iš originalo 2017-03-19.
McGrath P (2014-04-06). „Cancer virus discovery helped by delayed flight“. Health. BBC News. Suarchyvuota iš originalo 2015-10-08. Nuoroda tikrinta 2015-11-04.